A Single Site, Randomized, Double-blind, Placebo-controlled, Incremental Phase I Clinical Trial: to Evaluate the Tolerance, PK and PD Effects of TPN-672 Maleate in Chinese Healthy Volunteers After Single Dose Administration.
Latest Information Update: 17 Sep 2021
At a glance
- Drugs TPN 672 (Primary)
- Indications Pseudohypoaldosteronism
- Focus Adverse reactions; Pharmacokinetics
Most Recent Events
- 20 Dec 2019 Planned End Date changed from 17 Feb 2020 to 17 Dec 2020.
- 20 Dec 2019 Planned primary completion date changed from 17 Oct 2019 to 17 Oct 2020.
- 03 May 2019 New trial record